Varicella-Zoster Virus IgA Control Serum BC104A

$94.00

Summary

Virion/Serion Diagnostic Kit Control for research use (RUO)
Varicella-Zoster Virus IgA Control Serum
Applications: ELISA
IgA control serum
Ready-to-use; pre-diluted for SERION ELISA classic and SERION ELISA antigen assays
3 mL

SKU: BC104A Categories: control serum, Virion/Serion kits Tags: ELISA control serum, IgA, Varicella-Zoster Virus

Weight	1 lbs
Dimensions	9 × 5 × 2 in
target	Varicella-Zoster Virus reactive IgA
species reactivity	Varicella-Zoster Virus
applications	ELISA
assay type	Indirect & quantitative
available size	3 mL

Varicella-Zoster Virus IgA Control Serum BC104A

kit
Research area Infectious Disease
Storage Store at 2-8°C.
Associated products Varicella Zoster Virus (VZV) Envelope Glycoprotein E Control Antigen (BA104R02) Varicella-Zoster Virus Antigen (BA104VS) Varicella-Zoster Virus Glycoprotein Antigen (BA104VSG) Varicella-Zoster Virus IgA Control Serum (BC104A) Varicella-Zoster Virus IgG Control Serum (BC104G) Varicella-Zoster Virus IgM Control Serum (BC104M) Varicella-Zoster Virus IgA ELISA Kit (ESR104A) Varicella-Zoster Virus IgG ELISA Kit (ESR104G) Varicella-Zoster Virus IgM ELISA Kit (ESR104M)

target relevance

human antibody anti-Varicella-ZosterVirus

Varicella-ZosterVirus

Description
Virus that causes chickenpox (varicella) and shingles (herpes zoster)

Structure
Varicella-zoster virus (VZV), also known as Human herpesvirus 3 (HHV-3), is an enveloped, double-stranded DNA virus belonging to the genus Varicellovirus within the family Herpesviridae. The viral genome is enclosed within an icosahedral capsid surrounded by a protein tegument and a lipid envelope containing multiple glycoproteins that mediate host cell attachment and entry. Humans are the only known natural reservoir of the virus. Primary infection results in varicella (chickenpox), after which the virus establishes lifelong latency within sensory nerve ganglia. Reactivation of latent virus later in life results in herpes zoster (shingles). Varicella-zoster virus is highly contagious and spreads primarily through respiratory droplets, aerosolized virus from skin lesions, and direct contact with vesicular fluid.

Diagnosis
The diagnosis of varicella-zoster virus infection is performed through clinical evaluation, molecular testing, and serological methods. Polymerase chain reaction (PCR) is the preferred laboratory method due to its high sensitivity and specificity and can detect VZV DNA in vesicular fluid, lesion swabs, cerebrospinal fluid, blood, and tissue specimens. Direct fluorescent antibody testing and viral culture may also be used but are less sensitive than PCR. Serological assays, including ELISA-based tests, can detect VZV-specific IgM and IgG antibodies and are useful for determining immune status, previous exposure, or vaccine response. Laboratory confirmation is particularly important in atypical cases, immunocompromised patients, and individuals with suspected neurological complications.

Symptoms
Primary infection with varicella-zoster virus typically develops after an incubation period of approximately ten to twenty-one days and presents as chickenpox, characterized by fever, malaise, headache, and a generalized pruritic vesicular rash that progresses through macular, papular, vesicular, and crusting stages. Following recovery, the virus remains latent in sensory ganglia and may reactivate years or decades later as shingles. Herpes zoster is characterized by painful, unilateral vesicular eruptions distributed along affected dermatomes and is often preceded by burning, tingling, or localized pain. Complications of VZV infection include secondary bacterial skin infections, pneumonia, encephalitis, meningitis, cerebellitis, vision-threatening ophthalmic zoster, and postherpetic neuralgia, a chronic pain syndrome that may persist long after skin lesions have resolved. Severe disease is more common in elderly individuals, pregnant women, newborns, and immunocompromised patients.

Data

FAQ & Publications

Frequently Asked Questions

What is the intended application of the Varicella-Zoster Virus IgA Control Serum BC104A?

The Varicella-Zoster Virus IgA Control Serum BC104A is intended for use as an IgA control serum in ELISA assays, specifically compatible with SERION ELISA classic and SERION ELISA antigen assays.

How should the Varicella-Zoster Virus IgA Control Serum BC104A be stored to maintain stability?

This control serum should be stored at 2-8°C to ensure its stability and preserve its performance in downstream applications.

Is the Varicella-Zoster Virus IgA Control Serum BC104A species-specific?

Yes, the serum contains antibodies reactive to Varicella-Zoster Virus, which is species-specific to humans.

What volume is provided in a single vial of the Varicella-Zoster Virus IgA Control Serum BC104A?

Each vial contains 3 mL of ready-to-use, pre-diluted IgA control serum.

Does the Varicella-Zoster Virus IgA Control Serum BC104A support quantitative measurement in assays?

Yes, it is designed for indirect and quantitative ELISA assays to measure IgA antibodies reactive to Varicella-Zoster Virus.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.

Protocols

relevant to this product
BC104A protocol

Documents

#
Please enter your product and batch number here.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Varicella-Zoster Virus IgA Control Serum BC104A

Data

FAQ & Publications

Protocols

Documents

Related Technical Resources & Posts

Reviews

Related Products

Candida albicans IgA Control Serum BC117A

Yersinia IgA Control Serum BC138A

Campylobacter jejuni IgA Control Serum BC139A

Varicella-Zoster Virus IgG Control Serum BC104G

Brucella IgA Control Serum BC116A

Respiratory Syncytial Virus IgA Control Serum BC113A

Bordetella pertussis IgA Control Serum BC120A

Mycoplasma pneumoniae IgA Control Serum BC127A

Adenovirus IgA Control Serum BC128A

Helicobacter pylori IgA Control Serum BC118A

Enterovirus IgA Control Serum BC133A

Echovirus IgA Control Serum BC135A

Coxsackie IgA Virus Control Serum BC134A

Chlamydia trachomatis IgA Control Serum BC1372A

Chlamydia pneumoniae IgA Control Serum BC1371A